Timothy G. Majors
100 IP cases indexed. Covers patent matters.
Cases Presided Over
100 cases indexed | Page 4 of 4
Imperative Care, Inc. v.INARI MEDICAL, INC.
The Board found that the claims were unpatentable under obviousness (Grounds 3 and 4), specifically over a combination of Schaffer's valve with Hartley's string or Eller's wire. The decision hinged on finding that a POSA would have had reason to make this substitution, leading to predictable results in hemostatic device design.
Inari Agriculture, Inc. v.Corteva Agriscience LLC et al.
Inari Agriculture successfully petitioned to institute an IPR against Corteva Agriscience's GMO patents based on prior art from Barbour. The Board found a reasonable likelihood of prevailing regarding anticipation and obviousness over the cited publication, moving the case toward trial.
Inari Agriculture, Inc. v.Corteva Agriscience LLC et al.
The PTAB Board upheld the validity of U.S. Patent No. 8,901,378 B2 after finding that the TC1507 germplasm was publicly available prior to the application's filing date. The Board concluded that this availability satisfied priority requirements and prevented Barbour from qualifying as prior art under § 102.
Encube Ethicals Pvt. Ltd. v.Dermavant Sciences GmbH et al.
Encube Ethicals successfully challenged Dermavant Sciences' patent claims in the PTAB, leading to institution of the case. The Board found sufficient grounds for anticipation (102) and obviousness (103), specifically regarding psoriasis treatment methods. This decision significantly strengthens Encube's position by validating their prior art arguments against the '088 patent.
Integrated DNA Technologies, Inc. et al. v.Tecan Group AG
Integrated DNA Technologies successfully challenged the '108 patent's claims in a PTAB institution decision, finding reasonable likelihood of prevailing on anticipation for Claim 1. The Board affirmed that prior art disclosure was sufficient to support the enrichment limitation using Meyer et al.
Integrated DNA Technologies, Inc. et al. v.Tecan Group AG
Integrated DNA Technologies successfully petitioned IPR against Tecan Genomics' NGS patent (US 10036012), showing a reasonable likelihood that prior art (Meyer) anticipates claims. The Board granted institution, setting the stage for a full trial on all 22 challenged claims.
Integrated DNA Technologies, Inc. et al. v.Tecan Group AG
The PTAB issued a final written decision rejecting all grounds of unpatentability asserted by the Petitioner regarding NGS target enrichment claims. The Board adopted the Patent Owner's narrow definition of 'enrichment,' finding that the prior art failed to teach the claimed proportional increase in target fragments.
Integrated DNA Technologies, Inc. et al. v.Tecan Group AG
The PTAB upheld the patent against IPR challenges related to NGS target enrichment. The Board clarified that 'enrichment' requires an increased proportion of the sequence relative to others, not just a raw increase in fragment count. Petitioner failed to meet its burden of proof on unpatentability.
NEURENT MEDICAL INC. et al. v.The Foundry, LLC et al.
NEURENT MEDICAL INC. successfully petitioned PTAB for institution of IPR against THE FOUNDRY, LLC's nasal cavity treatment patent (11679077). The Board found sufficient evidence across multiple grounds of anticipation and obviousness to proceed to trial.
NEURENT MEDICAL INC. et al. v.The Foundry, LLC et al.
The Petitioner successfully demonstrated that multiple claims of the '077 patent were unpatentable over various combinations of prior art references. The Board found that a Person Having Ordinary Skill in the Art (POSA) would have been motivated to combine existing RF ablation and nasal treatment technologies.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.